Tag: pharmaceuticals

  • FDA Gives Accelerated Approval to Lymphoma Drug

    The U.S. Food and Drug Administration approved the drug Adcetris (brentuximab vedotin) developed by Seattle Genetics of Bothell, Washington, to treat two types of lymphoma. FDA approved Adcetris under an accelerated review procedure for promising drugs to treat serious diseases. Lymphoma is a type of cancer that affects the cells that play a role in…

  • Clinical Trial Shows Drug Improves Heart Muscle Functions

    A clinical trial conducted by University of Hull in the U.K. shows the drug omecamtiv mercabil improves the heart’s ability to pump blood in heart failure patients. The findings by Hull cardiology professor John Cleland and colleagues appear in the 20 August issue of the journal The Lancet (paid subscription required). Omecamtiv mercabil is one…

  • Roche to Build Canadian Pharmaceutical Development Center

    Roche Canada, a division of the global drug company based in Switzerland, says it will build a new pharmaceutical development center at its current site in Mississauga, Ontario near Toronto. The new center, says Roche, involves an investment of $190 million over the next five years, and will add 200 skilled staff. The new center…

  • FDA Issues Regulatory Science Modernization Plan

    The U.S. Food and Drug Administration today released its Strategic Plan for Regulatory Science that calls for modernization of the science used to protect the nation’s food and drug supplies. The plan describes the agency’s intent to improve the ways it develops and evaluates new products and materials, as well as improve the way it…

  • Clinical Trial to Test Stroke Treatment for Diabetics

    The University of Virginia Health System in Charlottesville has received a $25 million grant to lead a national clinical trial investigating a new treatment that could benefit ischemic stroke patients. The National Institutes of Neurological Diseases and Stroke, part of National Institutes of Health, is funding the study. Ischemic stroke occurs when a blood vessel…

  • New Technology Found to Treat Broad Range of Viruses

    Scientists at MIT’s Lincoln Laboratory in Lexington, Massachusetts have designed a class of therapies to identify cells that have been infected by any type of virus — from the common cold to Ebola — then kill those cells to terminate the infection. Their findings appear in the journal PLoS One. The technology targets a type…

  • UC San Diego Added to Pfizer Translational Network

    Pfizer Inc. in New York says University of California, San Diego Health Sciences will join the company’s network of translation research partnerships called Centers for Therapeutic Innovation (CTI). The company’s CTI partnerships now include life science research institutions in Massachusetts and New York, as well as California. Pfizer says it expects to spend some $50…

  • More Antidepressants Prescribed for Non-Psychiatric Disorders

    Researchers from Johns Hopkins University in Baltimore, Maryland and Columbia University in New York find that the rapid growth of prescriptions for antidepressant medications has been fueled by orders from non-psychiatrist providers and without any psychiatric diagnosis. The paper by Ramin Mojtabai of Johns Hopkins and Columbia’s Mark Olfson appears in the August 2011 issue…

  • FDA Approves First Treatment for Scorpion Stings

    The Food and Drug Administration approved Anascorp, the first specific treatment for a sting by Centruroides scorpions, commonly known as the Arizona Bark Scorpion in the United States. The drug was developed by Rare Disease Therapeutics Inc. in Franklin, Tennessee, licensing research by University of Arizona in Tucson and and two research institutes in Mexico.…

  • Candidate Drug Starves Cancer Cells of Energy Source

    Researchers from the U.S., Canada, and New Zealand have identified a compound that deprives some cancer cells of their energy source, the sugar glucose. The compound is packaged in a drug candidate licensed for pre-clinical testing to a company founded by one of the study’s senior authors. The findings appear in the 3 August issue…